Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jody Roach

Nurse Practitioner, Gerontology Zanesville, OH Nurse Practitioner

NPI 1467976993 CMS profile 3434071

2951 Maple Ave, Zanesville, OH 43701

Open in the dashboard

General payments

$2,540

128 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jody Roach of Zanesville, OH is reported in the CMS Open Payments database as having received $2,540 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $459 19
2024 General $817 37
2023 General $1,263 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jody Roach
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Jody Roach were reported at $459. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Jody Roach Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $1,263 $158 $53–$482 $160
2024 $817 $171 $55–$533 $164
2025 $459 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $423 25 payments
  2. Janssen Biotech, Inc. $415 18 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $290 20 payments
  4. Regeneron Healthcare Solutions, Inc. $234 11 payments
  5. QOL Medical, LLC $178 9 payments
  6. Genzyme Corporation $174 5 payments
  7. Phathom Pharmaceuticals, Inc. $143 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $108 4 payments
  9. Pfizer Inc. $85 4 payments
  10. Madrigal Pharmaceuticals $64 1 payment
  11. Other $426 24 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,339 125 payments
  2. Education $201 3 payments
Products named General payments · program years 2023–2025
  1. STELARA $415 18 payments
  2. XIFAXAN $225 15 payments
  3. DUPIXENT Inflammation And Immunology $205 10 payments
  4. LINZESS $203 16 payments
  5. DUPIXENT Immunology $174 5 payments
  6. RINVOQ $165 6 payments
  7. Sucraid $158 8 payments
  8. CREON $156 11 payments
  9. SIMPONI ARIA $126 9 payments
  10. SIMPONI $126 9 payments
  11. Other $1,256 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

666

Median for Nurse Practitioner: 389

Drug cost

$181,157

Median for Nurse Practitioner: $21,885

Branded share of claims

35.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 11 $143,829
Linzess Linaclotide Brand 15 $21,315
Sucralfate Generic 48 $4,426
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 71 $4,398
Cholestyramine Cholestyramine (With Sugar) Brand 20 $1,872
Pantoprazole Sodium Generic 182 $1,821
Omeprazole Generic 146 $1,582
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 66 $760
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 56 $665
Dicyclomine Hcl Generic 21 $289

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$24,139

Medicare's payments for the services billed

Medicare patients

179

Average age 71

Services billed

352

114 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 39%
Diabetes 32%
Depression 31%
Atrial fibrillation 26%
COPD 26%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $90
  • Regeneron Healthcare Solutions, Inc. $76
$166 — —
RINVOQ
  • AbbVie, Inc. $108
$108 — —
STELARA
  • Janssen Biotech, Inc. $95
$95 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $82
$82 — —
Sucraid
  • QOL Medical, LLC $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record